Background and Aims: Previous investigations have revealed that microRNAs (miRNAs) can function as oncogenes or tumor suppressors in chronic lymphocytic leukemia (CLL) and that the expression of miRNAs, such as miR-485-3p changes in several illnesses. This study was designed to determine the expression level of miR-485-3p and its target FOXD3 in CLL patients and controls to identify if this miR...

Chronic lymphocytic leukemia (CLL), the most frequent type of leukemia in western countries, is characterized by the progressive accumulation in blood, bone marrow and lymphoid tissues of monoclonal B lymphocytes with a characteristic immunophenotype. Despite advances in therapy and improved outcome, in most instances CLL is an incurable disorder. Signaling via the B-cell receptor (BCR), the up...

Palatal involvement in chronic lymphocytic leukemia (CLL) is rare and has only been reported 3 previous times in the non-radiology literature. To our knowledge this is the first imaging description of this entity. Based on our experience, when smoothly lobulated, homogeneous masses are identified on the oral surface of the hard palate, the diagnosis of CLL should be considered.

Transformation to a large cell lymphoma may occur during the course of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in approximately 5% of the cases. This is known as Richter's transformation. A much less frequent transformation to Hodgkin lymphoma may occur. We report a case of CLL/SLL in which a transformation to Hodgkin lymphoma occurred, and we review previously publish...

BACKGROUND AND OBJECTIVES The potential anticancer agent 1-(2-chlorophenyl-N-methylpropyl)-3-isoquinolinecarboxamide (PK11195), a translocator protein (18KDa) (TSPO) ligand, facilitates the induction of cell death by a variety of cytotoxic and chemotherapeutic agents. Primary chronic lymphocytic leukemia (CLL) cells overexpress TSPO. The aim of this study was to examine the effects of PK11195 o...

PI3K signaling is now targeted in first clinical trials in patients with B cell malignancies, including Chronic Lymphocytic Leukemia (CLL), which represent one of the first molecularly targeted therapies for B cell malignancies.

In this issue of Blood, Krysov et al demonstrate that B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) results in partial activation of the unfolded protein response (UPR).

In this issue of Blood, te Raa et al report that cytomegalovirus (CMV)-specific CD8+ T-cell function is preserved in chronic lymphocytic leukemia (CLL), on a background of global T-cell dysfunction.